FDA approval of Izervay tops recent ophthalmology news
Healio’s top ophthalmology items so far in August include the FDA approval of Izervay for geographic atrophy and phase 3 results of OCS-01 eye drops for the treatment of inflammation and pain after cataract surgery.
Check out these items and more below.
Healio’s top ophthalmology items so far in August include the FDA approval of Izervay for geographic atrophy and phase 3 results of OCS-01 eye drops for the treatment of inflammation and pain after cataract surgery. Image: Adobe Stock
Izervay receives FDA approval for geographic atrophy
The FDA approved Izervay, a complement C5 inhibitor, for the treatment of geographic atrophy secondary to age-related macular degeneration, according to a press release from Astellas Pharma. Read more.
Burden of geographic atrophy high on patients, caregivers
SEATTLE — In the U.S. and Canada, the burden of geographic atrophy on patients and caregivers is “substantial and multifaceted,” according to a study presented at the American Society of Retina Specialists annual meeting. Read more.
BLOG: Associate physicians: Dance with the one(s) who brought you
If you’re an owner of a practice that has decided to pursue a sale transaction, you have likely been working for months with your partners and advisers to explore the market, evaluate potential buyers and negotiate key deal terms. Read more.
OCS-01 eye drops reduce inflammation, pain after cataract surgery in phase 3 trial
OCS-01 eye drops demonstrated positive topline results for the treatment of inflammation and pain after cataract surgery, according to a press release from Oculis. Read more.
Cognitive outcomes not significantly different after ROP treatment with bevacizumab, laser
SEATTLE — There was no significant difference in cognitive outcomes for patients with retinopathy of prematurity treated with intravitreal bevacizumab compared with those treated with laser photocoagulation, according to a speaker here. Read more.